Comparing two chemotherapy combinations after surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study compares two different chemotherapy combinations after surgery for pancreatic cancer. The goal is to see which is better at preventing the cancer from coming back. You would receive either liposomal irinotecan with oxaliplatin and S-1, or gemcitabine with capecitabine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have had surgery to remove your pancreatic cancer, and the surgeon was able to remove all visible cancer (R0 or R1).
- You can start treatment within 12 weeks after your surgery.
- You should be generally active and able to take care of yourself (ECOG 0-1).
- You have not had chemotherapy or radiation before this surgery.
- Your cancer has not spread to other parts of your body.
- You do not have certain genetic conditions that could make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial compares two different chemotherapy combinations given after surgery to lower the chance of pancreatic cancer coming back. One combines a new drug (HR070803) with two standard drugs (oxaliplatin and S-1), and the other uses a standard three-drug regimen (NALIRIFOX).
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.